Journal article · 2012 · Open access

Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy

Maj‐Linda B. Selenica, Milene Lara Brownlow, Jeffy P. Jimenez, Daniel C. Lee, Gabriela Pena, Chad A. Dickey, Marcia N. Gordon, David Morgan

Neurodegenerative Diseases, 11(4), 165–181 · Published 10 July 2012 · DOI 10.1159/000337230

Read the free full textView at the publisherCite this paper

In brief

“Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy” is a 2012 journal article by Maj‐Linda B. Selenica and 7 co-authors, published in Neurodegenerative Diseases. OpenAlex counts 10,395 citations as of 15 November 2026, which puts it in the top 1% of works published in 2012 by citations. It is open access: the full text is free to read at PubMed Central.

Citations
10,395
Most cited in
2022 (937)
Field-weighted impact
165.19
References
185
Authors
8

Abstract

BACKGROUND: We aimed to investigate the influence of oligomeric forms of β-amyloid (Aβ) and the influence of the duration of exposure on the development of tau phosphorylation. METHODS: Aβ oligomers were injected intracranially either acutely into 5-month-old rTg4510 mice and tissue was collected 3 days later, or chronically into 3-month-old mice and tissue was collected 2 months later. Several forms of phosphorylated tau (p-tau), GSK3 (glycogen synthase kinase-3) and microglial and astrocyte activation were measured. RESULTS: Acute injections of Aβ oligomers had no effect on p-tau epitopes but did result in elevation of phosphorylated/activated GSK3 (pGSK3). Chronic infusion of Aβ oligomers into the right hippocampus resulted in 3- to 4-fold elevations in several p-tau isoforms with no changes in total tau levels. A significant elevation in pGSK3 accompanied these changes. Microglial staining with CD68 paralleled the increase in tau phosphorylation, however, CD45 staining was unaffected by Aβ. Control experiments revealed that the infusion of Aβ from the minipumps was largely complete by 10 days after implantation. Thus, the elevation in p-tau 2 months after implantation implies that the changes are quite persistent. CONCLUSION: Soluble Aβ(1-42) oligomers have long-lasting effects on tau phosphorylation in the rTg4510 model, possibly due to elevations in GSK3. These data suggest that even brief elevations in Aβ production, may have enduring impact on the risk for tauopathy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Selenica, M. B., Brownlow, M. L., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2012). Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy. Neurodegenerative Diseases, 11(4), 165–181. https://doi.org/10.1159/000337230

MLA 9

Selenica, Maj‐Linda B., et al. “Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy.” Neurodegenerative Diseases, vol. 11, no. 4, 2012, pp. 165–181. https://doi.org/10.1159/000337230.

Chicago

Selenica, Maj‐Linda B., Milene Lara Brownlow, Jeffy P. Jimenez, Daniel C. Lee, Gabriela Pena, Chad A. Dickey, Marcia N. Gordon, and David Morgan. 2012. “Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy.” Neurodegenerative Diseases 11 (4): 165–181. https://doi.org/10.1159/000337230.

Harvard

Selenica, M. B. et al. (2012) ‘Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy’, Neurodegenerative Diseases, 11(4), pp. 165–181. doi:10.1159/000337230.

IEEE

M. B. Selenica et al., “Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy,” Neurodegenerative Diseases, vol. 11, no. 4, pp. 165–181, 2012, doi: 10.1159/000337230.

BibTeX

@article{selenica2012amyloid,
  title     = {{Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy}},
  author    = {Selenica, Maj‐Linda B. and Brownlow, Milene Lara and Jimenez, Jeffy P. and Lee, Daniel C. and Pena, Gabriela and Dickey, Chad A. and Gordon, Marcia N. and Morgan, David},
  journal   = {Neurodegenerative Diseases},
  year      = {2012},
  volume    = {11},
  number    = {4},
  pages     = {165--181},
  doi       = {10.1159/000337230},
  url       = {https://doi.org/10.1159/000337230}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
2017836836
2018813813
2019695695
2020707707
2021768768
2022937937
2023873873
2024673673
2025284284
20261212

Its field-weighted citation impact is 165.19: it has been cited 165.19 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • amyloid-beta oligomers
  • tau phosphorylation
  • tauopathy
  • glycogen synthase kinase-3
  • rTg4510 mice
  • microglial activation
  • astrocyte activation
  • hippocampus

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Selenica, M. B., Brownlow, M. L., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2012). Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy. Neurodegenerative Diseases, 11(4), 165–181. https://doi.org/10.1159/000337230

How many times has this paper been cited?

10,395 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at PubMed Central.

Who wrote this paper?

Maj‐Linda B. Selenica, Milene Lara Brownlow, Jeffy P. Jimenez, Daniel C. Lee, Gabriela Pena, Chad A. Dickey, Marcia N. Gordon, David Morgan.

What is the DOI of this paper?

10.1159/000337230. The permanent link is https://doi.org/10.1159/000337230.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.